389 completed. 389 Phase 3, 44 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 389 | Completed 389 |
| Phase 2 | 44 | Completed 44 |
Follow Gastroenteritis: new trials by email Literature Review of Gastroenteritis trials Research Report on Gastroenteritis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 7 Days vs. 14 Days of Vonoprazan-based Triple Therapy for H. Pylori Eradication Vonoprazan, Amoxicillin, Clarithromycin - Helicobacter Pylori Infection, Gastritis | Phase 3 | Completed | Alexandria University | 326 | 2024-06-30 | 2025-02-11 |
| The Effects of Bromelain Supplement in Patients With Ulcerative Colitis Bromlein, Placebo - Ulcerative Colitis, Primary Sclerosing Cholangitis | Phase 2 / Phase 3 | Completed | National Nutrition and Food Technology Institute | 52 | 2024-04-20 | 2026-10-27 |
| A Study on the Immune Response and Safety of Inactivated Poliovirus Vaccine (IPV) When Co-administered With Human Rotavirus (HRV) Porcine Circovirus (PCV)-Free Vaccine in Healthy Chinese Infants HRV PCV-free, IPV - Gastroenteritis | Phase 3 | Completed | GlaxoSmithKline | 400 | 2024-03-22 | 2025-10-22 |
| A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis Mirikizumab IV, Mirikizumab SC - Ulcerative Colitis | Phase 3 | Completed | Eli Lilly and Company | 63 | 2023-11-22 | 2026-06-03 |
| Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Rotarix Porcine Circovirus (PCV)-Free Liquid Compared to Rotarix Liquid Given in 2-doses in Healthy Chinese Infants Starting at Age 6-16 Weeks GSK's liquid oral live attenuated HRV, PCV-free liquid formulation of GSK's oral live attenuated HRV - Gastroenteritis | Phase 3 | Completed | GlaxoSmithKline | 2000 | 2023-09-01 | 2025-05-09 |
| Dapagliflozin in Patients With Ulcerative Colitis Mesalamine, Dapagliflozin 10mg Tab - Inflammatory Bowel Diseases | Phase 2 / Phase 3 | Completed | Mostafa Bahaa | 60 | 2023-08-20 | 2026-09-21 |
| Clinical Study to Evaluate the Possible Efficacy of Nifuroxazide in Patient With Ulcerative Colitis Mesalamine, Nifuroxazide - Inflammatory Bowel Diseases | Phase 2 / Phase 3 | Completed | Mostafa Bahaa | 50 | 2023-08-20 | 2026-10-13 |
| Safety and Immunogenicity of HIL-214 With Routine Pediatric Vaccines HIL-214, Placebo - Gastroenteritis | Phase 2 / Phase 3 | Completed | HilleVax | 329 | 2023-06-10 | 2025-03-12 |
| Comparison of Ketorolac at Three Doses in Children With Acute Pain Ketorolac Tromethamine - Acute Pain, Abdominal Pain | Phase 3 | Completed | Hamilton Health Sciences Corporation | 171 | 2023-06-01 | 2025-07-09 |
| A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis Mirikizumab - Ulcerative Colitis, Ulcerative Colitis Chronic | Phase 3 | Completed | Eli Lilly and Company | 172 | 2023-05-17 | 2026-06-10 |
| A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile Infection RBX2660 - Clostridium Difficile Infection Recurrence | Phase 3 | Completed | Ferring Pharmaceuticals | 41 | 2023-04-21 | 2026-04-24 |
| Fenofibrate in Ulcerative Colitis Mesalamine, Fenofibrate 160mg - Inflammatory Bowel Diseases | Phase 2 / Phase 3 | Completed | Tanta University | 60 | 2023-02-28 | 2026-05-04 |
| Bowel Preparation Regimen for Colon Capsule Endoscopy Procedure polyethylene glycol, sodium phosphate, polyethylene glycol + ascorbic acid - Colon Cancer, Inflammatory Bowel Diseases | Phase 3 | Completed | Region Skane | 147 | 2023-02-01 | 2024-02-28 |
| ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2 ABX464, Placebo - Ulcerative Colitis | Phase 3 | Completed | Abivax S.A. | 636 | 2023-01-25 | 2026-09-10 |
| 24-Week Induction Study of APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE 3) APT-1011, Placebo oral tablet, Esophagogastroduodenoscopy - Eosinophilic Esophagitis | Phase 3 | Completed | Ellodi Pharmaceuticals, LP | 218 | 2022-12-29 | 2025-08-13 |
| ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1 ABX464, Placebo - Ulcerative Colitis | Phase 3 | Completed | Abivax S.A. | 639 | 2022-11-16 | 2026-09-10 |
| Cholecalciferol Comedication in IBD - the 5C-study Vitamin D3 - Inflammatory Bowel Diseases | Phase 3 | Completed | University Hospital, Basel, Switzerland | 150 | 2022-09-21 | 2024-12-24 |
| Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis CC-93538 - Eosinophilic Esophagitis | Phase 3 | Completed | Celgene | 367 | 2022-08-09 | 2026-04-06 |
| Effect of Pentoxifylline Versus Probiotic on Preterm Neonates With Necrotizing Enterocolitis Pentoxifylline, Probiotic Formula - Necrotizing Enterocolitis | Phase 3 | Completed | Tanta University | 75 | 2022-06-30 | 2024-05-20 |
| A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Japanese Participants With Eosinophilic Gastroenteritis CC-93538, Placebo - Eosinophilic Gastroenteritis | Phase 3 | Completed | Celgene | 48 | 2022-03-04 | 2026-09-14 |
Showing 20 of 389. Sign in to see all of them.
Colitis, Ulcerative (123) · Crohn Disease (122) · Inflammatory Bowel Diseases (48) · Eosinophilic Esophagitis (20) · Diarrhea (18) · Esophagitis, Peptic (15) · Mucositis (15) · Colitis (14) · Appendicitis (12) · Gastrointestinal Diseases (12) · Esophagitis (10) · Enterocolitis, Necrotizing (9) · Gastroesophageal Reflux (8) · Diverticulitis (7)
Digestive System Diseases (383) · Gastrointestinal Diseases (377) · Intestinal Diseases (310) · Inflammatory Bowel Diseases (202) · Colonic Diseases (134) · Colitis (119) · Pathological Conditions, Signs and Symptoms (54) · Infections (40) · Esophageal Diseases (33) · Hemic and Lymphatic Diseases (32) · Esophagitis (29) · Hematologic Diseases (28) · Signs and Symptoms (27) · Immune System Diseases (26)
Mesalamine (41) · Adalimumab (34) · Budesonide (18) · Infliximab (18) · Certolizumab Pegol (10) · Ustekinumab (10) · vedolizumab (10) · Probiotics (7) · Lansoprazole (6) · etrolizumab (6) · Azathioprine (5) · Dexlansoprazole (5) · Esomeprazole (5) · Fluticasone (5) · mirikizumab (5)
Takeda (16) · AbbVie (14) · Abbott (14) · Bausch Health Americas, Inc. (14) · Dr. Falk Pharma GmbH (12) · Shire (11) · Centocor, Inc. (8) · Ferring Pharmaceuticals (8) · Janssen Research & Development, LLC (8) · Celgene (7) · UCB Pharma (7) · AstraZeneca (6) · GlaxoSmithKline (6) · Hoffmann-La Roche (6) · Pfizer (6)
United States (188) · Canada (126) · Germany (103) · Belgium (92) · Poland (89) · United Kingdom (80) · France (79) · Czechia (77) · Italy (76) · Israel (74) · Australia (72) · Hungary (72) · Spain (67) · Japan (64) · Netherlands (63)
PMID 29380251, PMID 32445184, PMID 37368103, PMID 19735233, PMID 20195905, PMID 26893500, PMID 29850873, PMID 30476584, PMID 31077827, PMID 31599001, PMID 32635680, PMID 32766762, PMID 32816215, PMID 32870265, PMID 32964215, PMID 33324993, PMID 33684552, PMID 34614208, PMID 35648151, PMID 35792493, PMID 36124702, PMID 36336750, PMID 36342120, PMID 36526796, PMID 36931693, PMID 37402275, PMID 37560161, PMID 38310565, PMID 38425446, PMID 40357993, PMID 21129076, PMID 25996351, PMID 26563167, PMID 27959607, PMID 28467869, PMID 29028981, PMID 29142515, PMID 29409871, PMID 29743836, PMID 29857145, PMID 29909019, PMID 30203005, PMID 30739254, PMID 31279870, PMID 33127596, PMID 33513294, PMID 34035832, PMID 34077627, PMID 34165201, PMID 35380664
2015 (10), 2016 (10), 2017 (10), 2004 (6), 2014 (6), 2018 (6), 2019 (6), 2008 (5), 2023 (3), 2005 (2), 2009 (1), K01DK075478 (1), M01RR000070 (1), M01RR000997 (1), P30CA068485 (1)